Solvonis Therapeutics plc (LON:SVNS)
0.1650
+0.0200 (13.79%)
At close: May 9, 2025, 4:30 PM BST
Solvonis Therapeutics Balance Sheet
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2021 | 2018 - 2020 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | May '21 May 31, 2021 | 2018 - 2020 |
Cash & Equivalents | 0.76 | 0.16 | 1.64 | 0.6 | 0.04 | Upgrade
|
Cash & Short-Term Investments | 0.76 | 0.16 | 1.64 | 0.6 | 0.04 | Upgrade
|
Cash Growth | 388.39% | -90.55% | 174.25% | 1433.33% | 56.00% | Upgrade
|
Accounts Receivable | - | 0.07 | 0.04 | 0.02 | 0.04 | Upgrade
|
Other Receivables | 0.04 | 0.02 | 0.06 | 0.12 | 0.04 | Upgrade
|
Receivables | 0.04 | 0.09 | 0.1 | 0.14 | 0.09 | Upgrade
|
Inventory | - | 0.05 | 0.19 | - | - | Upgrade
|
Prepaid Expenses | 0.02 | 0.02 | 0.23 | - | - | Upgrade
|
Total Current Assets | 0.82 | 0.31 | 2.16 | 0.74 | 0.13 | Upgrade
|
Property, Plant & Equipment | - | 0.04 | 0.7 | 0.31 | 0.36 | Upgrade
|
Other Intangible Assets | 2.09 | 2.07 | 2.07 | 2.07 | 2.07 | Upgrade
|
Other Long-Term Assets | 0.3 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
Total Assets | 3.2 | 2.43 | 4.94 | 3.13 | 2.57 | Upgrade
|
Accounts Payable | 0.08 | 0.16 | 0.19 | 0.84 | 0.42 | Upgrade
|
Accrued Expenses | 0.04 | 0.09 | 0.14 | 0.52 | 0.22 | Upgrade
|
Short-Term Debt | - | - | - | 0.96 | 0.65 | Upgrade
|
Current Portion of Leases | - | 0.01 | 0 | - | - | Upgrade
|
Current Unearned Revenue | - | 0.09 | 0.04 | - | - | Upgrade
|
Other Current Liabilities | - | 0.03 | - | - | 0.03 | Upgrade
|
Total Current Liabilities | 0.12 | 0.39 | 0.37 | 2.32 | 1.32 | Upgrade
|
Long-Term Leases | - | 0.02 | 0.02 | - | - | Upgrade
|
Total Liabilities | 0.12 | 0.41 | 0.39 | 2.32 | 1.32 | Upgrade
|
Common Stock | 2.23 | 0.04 | 0.04 | 0.01 | 0.01 | Upgrade
|
Additional Paid-In Capital | 7.36 | 7 | 7 | 0.94 | 0.94 | Upgrade
|
Retained Earnings | -10.56 | -8.97 | -5.85 | -3.14 | -2.19 | Upgrade
|
Comprehensive Income & Other | 4.04 | 3.95 | 3.36 | 3 | 2.48 | Upgrade
|
Shareholders' Equity | 3.08 | 2.03 | 4.55 | 0.81 | 1.25 | Upgrade
|
Total Liabilities & Equity | 3.2 | 2.43 | 4.94 | 3.13 | 2.57 | Upgrade
|
Total Debt | - | 0.03 | 0.02 | 0.96 | 0.65 | Upgrade
|
Net Cash (Debt) | 0.76 | 0.12 | 1.62 | -0.36 | -0.62 | Upgrade
|
Net Cash Growth | 525.62% | -92.52% | - | - | - | Upgrade
|
Net Cash Per Share | 0.00 | 0.00 | 0.02 | -0.01 | -0.01 | Upgrade
|
Filing Date Shares Outstanding | 2,296 | 124.76 | 104.1 | 70 | 69 | Upgrade
|
Total Common Shares Outstanding | 2,296 | 104.1 | 104.1 | 70 | 69 | Upgrade
|
Working Capital | 0.7 | -0.07 | 1.79 | -1.58 | -1.2 | Upgrade
|
Book Value Per Share | 0.00 | 0.02 | 0.04 | 0.01 | 0.02 | Upgrade
|
Tangible Book Value | 1 | -0.04 | 2.49 | -1.26 | -0.82 | Upgrade
|
Tangible Book Value Per Share | 0.00 | -0.00 | 0.02 | -0.02 | -0.01 | Upgrade
|
Machinery | - | - | 0.94 | 0.54 | 0.55 | Upgrade
|
Leasehold Improvements | - | - | 0.09 | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.